Literature DB >> 7594661

Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine.

F Mascart-Lemone1, M Gérard, M Libin, A Crusiaux, P Franchioly, A Lambrechts, M Goldman, N Clumeck.   

Abstract

The IgA, IgM, and IgG antibody responses to pneumococcal polysaccharide vaccine were analyzed in 35 asymptomatic or mildly symptomatic human immunodeficiency virus (HIV)-infected patients stratified according to their CD4 cell counts and in 12 healthy controls. Both the antibody titers in serum and saliva and the numbers of circulating antigen-specific antibody-producing cells (Elispot technique) were measured. At the peak of the antibody responses, HIV-infected patients mounted nearly normal IgG responses, while their IgM responses were significantly depressed, regardless of their CD4 cell counts. The IgA antibody response was decreased in patients with < 500 CD4 circulating cells/mm3. Most IgG antibodies belonged to the IgG2 subclass, and most IgA antibodies were dimeric IgA2 in both controls and patients. Anti-capsular pneumococcal polysaccharide IgG titers decreased much more rapidly in HIV-infected patients so that in all groups they were significantly lower than in controls 9 months after vaccination.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594661     DOI: 10.1093/infdis/172.5.1253

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Impact of pneumococcal vaccination in Senegalese HIV-1-infected children.

Authors:  Tandakha Dieye; Thierry Simonart; Papa S Sow; Ngagne M'Baye; Souleymane M'Boup; Claire-Michèle Farber
Journal:  Eur J Pediatr       Date:  2002-02       Impact factor: 3.183

2.  Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets.

Authors:  Leen Moens; Bert Verbinnen; Kris Covens; Greet Wuyts; Marina Johnson; Lucy Roalfe; David Goldblatt; Isabelle Meyts; Xavier Bossuyt
Journal:  Infect Immun       Date:  2015-05-04       Impact factor: 3.441

Review 3.  Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis.

Authors:  Solen Kernéis; Odile Launay; Clément Turbelin; Frédéric Batteux; Thomas Hanslik; Pierre-Yves Boëlle
Journal:  Clin Infect Dis       Date:  2014-01-10       Impact factor: 9.079

4.  CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency.

Authors:  Menno C van Zelm; Julie Smet; Brigitte Adams; Françoise Mascart; Liliane Schandené; Françoise Janssen; Alina Ferster; Chiung-Chi Kuo; Shoshana Levy; Jacques J M van Dongen; Mirjam van der Burg
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

5.  SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination.

Authors:  Nichole R Klatt; Carol L Vinton; Rebecca M Lynch; Lauren A Canary; Jason Ho; Patricia A Darrah; Jacob D Estes; Robert A Seder; Susan L Moir; Jason M Brenchley
Journal:  Blood       Date:  2011-09-29       Impact factor: 22.113

6.  Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population: proposal for response criteria.

Authors:  M J Rodrigo; M Miravitlles; M J Cruz; J de Gracia; M Vendrell; C Pascual; F Morell
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

Review 7.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Optimal assessment of the ability of children with recurrent respiratory tract infections to produce anti-polysaccharide antibodies.

Authors:  D Tuerlinckx; F Vermeulen; V Pékus; G de Bilderling; Y Glupczynski; S Collet; J Jamart; E Bodart; F Mascart
Journal:  Clin Exp Immunol       Date:  2007-05-18       Impact factor: 4.330

9.  Risk factors in HIV-1-infected patients developing repetitive bacterial infections: toxicological, clinical, specific antibody class responses, opsonophagocytosis and Fc(gamma) RIIa polymorphism characteristics.

Authors:  A Payeras; P Martinez; J Milà; M Riera; A Pareja; J Casal; N Matamoros
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

10.  Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.

Authors:  Francesca Lombardi; Simone Belmonti; Massimiliano Fabbiani; Matteo Morandi; Barbara Rossetti; Giacinta Tordini; Roberto Cauda; Andrea De Luca; Simona Di Giambenedetto; Francesca Montagnani
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.